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Abstract
Background—Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by 
inhibiting the activity of the Niemann–Pick C1-like 1 (NPC1L1) protein. However, whether such 
inhibition reduces the risk of coronary heart disease is not known. Human mutations that 
inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be 
used to infer potential effects of that drug.
Methods—We sequenced the exons of NPC1L1 in 7364 patients with coronary heart disease and 
in 14,728 controls without such disease who were of European, African, or South Asian ancestry. 
We identified carriers of inactivating mutations (nonsense, splice-site, or frameshift mutations). In 
addition, we genotyped a specific inactivating mutation (p.Arg406X) in 22,590 patients with 
coronary heart disease and in 68,412 controls. We tested the association between the presence of 
an inactivating mutation and both plasma lipid levels and the risk of coronary heart disease.
Results—With sequencing, we identified 15 distinct NPC1L1 inactivating mutations; 
approximately 1 in every 650 persons was a heterozygous carrier for 1 of these mutations. 
Heterozygous carriers of NPC1L1 inactivating mutations had a mean LDL cholesterol level that 
was 12 mg per deciliter (0.31 mmol per liter) lower than that in noncarriers (P = 0.04). Carrier 
status was associated with a relative reduction of 53% in the risk of coronary heart disease (odds 
ratio for carriers, 0.47; 95% confidence interval, 0.25 to 0.87; P = 0.008). In total, only 11 of 
29,954 patients with coronary heart disease had an inactivating mutation (carrier frequency, 
0.04%) in contrast to 71 of 83,140 controls (carrier frequency, 0.09%).
Conclusions—Naturally occurring mutations that disrupt NPC1L1 function were found to be 
associated with reduced plasma LDL cholesterol levels and a reduced risk of coronary heart 
disease. (Funded by the National Institutes of Health and others.)
Ezetimibe, a drug that is commonly prescribed to reduce plasma levels of low-density 
lipoprotein (LDL) cholesterol, inhibits the function of the protein encoded by the Niemann–
Pick C1-like 1 gene (NPC1L1).1 NPC1L1 protein, which is expressed in the small intestine 
and liver, functions as a transporter of dietary cholesterol from the gut lumen into intestinal 
enterocytes.2,3 Because of its ability to block sterol absorption by about 50%,4 ezetimibe 
lowers plasma LDL cholesterol levels by 15 to 20%.5 However, it is uncertain whether 
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inhibiting NPC1L1 — either through ezetimibe treatment or by other means — reduces the 
risk of clinical coronary heart disease.6
Naturally occurring DNA sequence variants in humans that affect the activity of one or more 
protein targets can be used to estimate the potential efficacy and toxicity of a drug targeting 
such proteins.7,8 Genomewide association studies have identified common DNA sequence 
variants in NPC1L1 associated with modest alterations in plasma LDL cholesterol levels.9 
However, it is difficult to discern precisely how variants that are discovered through 
genomewide association studies affect the activity of a gene.
In contrast, some DNA mutations that arise in the protein-coding sequence can completely 
inactivate a gene. Inactivating mutations can be single-base changes that introduce a stop 
codon and that lead to premature truncation of a protein (nonsense mutations), insertions or 
deletions (indels) of DNA that scramble the protein translation beyond the variant site 
(frameshift mutations), or point mutations at modification sites of the nascent pre–
messenger RNA transcript that alter the splicing process10 (splice-site mutations). Because 
such mutations — which are variously termed protein-disruptive, protein-inactivating, loss-
of-function, or null — profoundly affect protein function, they are typically very rare in the 
population as a consequence of natural selection.
We tested the hypothesis that protein-inactivating mutations in NPC1L1 reduce both the 
LDL cholesterol level and the risk of coronary heart disease. We sequenced the coding 
regions of NPC1L1 in a large number of persons, identified carriers of mutations that 
inactivate this gene, and determined whether persons who carry a heterozygous inactivating 
mutation had a lower LDL cholesterol level and a lower risk of coronary heart disease than 
noncarriers of these mutations.
Methods
Study Design
We conducted this study using data and DNA samples from 16 case–control studies and 
cohort studies. All study participants provided written informed consent for genetic studies. 
The first and last authors designed the study. The institutional review boards at the Broad 
Institute and each participating site approved the study protocols. The first and last authors 
vouch for the accuracy and completeness of the data and all analyses.
Study Participants
During the first phase of the study, we sequenced the 20 protein-coding exons in NPC1L1 in 
samples obtained from 22,092 participants from seven case–control studies and two 
prospective cohort studies (see Table S1 in the Supplementary Appendix, available with the 
full text of this article at NEJM.org). The case–control studies included the Exome 
Sequencing Project Early-Onset Myocardial Infarction (ESP-EOMI) study conducted by the 
National Heart, Lung, and Blood Institute,11 the Italian Atherosclerosis Thrombosis and 
Vascular Biology (ATVB) study,12 the Ottawa Heart Study (OHS),13 the Precocious 
Coronary Artery Disease (PROCARDIS) study,14 the Pakistan Risk of Myocardial 
Infarction Study (PROMIS),15 the Registre Gironi del COR (Gerona Heart Registry or 
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REGICOR) study,16 and the Munich Myocardial Infarction (Munich-MI) study.17 The 
prospective cohort studies included the Atherosclerosis Risk in Communities (ARIC) 
study18 and the Jackson Heart Study (JHS).19
During the second phase of the study, we genotyped the most common inactivating mutation 
in NPC1L1 on the basis of data obtained during the sequencing phase (p.Arg406X) in nine 
independent sample sets from a total of 91,002 participants (Table S2 in the Supplementary 
Appendix). These nine sample sets were from participants in the ARIC study (participants 
who did not undergo sequencing), the Vanderbilt University Medical Center Biorepository 
(BioVU),20 the Genetics of Diabetes Audit and Research Tayside (GoDARTS) study,21 the 
German North and German South Coronary Artery Disease studies,22 the Mayo Vascular 
Diseases Biorepository (Mayo),23 PROCARDIS (participants who did not undergo 
sequencing), the Women’s Genome Health Study (WGHS),24 and the Women’s Health 
Initiative (WHI).25
Clinical Data
Data obtained for all the participants from both the sequencing and genotyping phases of the 
study included a medical history and laboratory assessment for cardiovascular risk factors, 
as described previously for each study. The participants were of African ancestry (2836 
participants from ARIC, 2251 from JHS, and 455 from ESP-EOMI), South Asian ancestry 
(1951 participants from PROMIS), or European ancestry (all the other participants).
For each study cohort, available clinical data were used to define coronary heart disease. 
The definitions, which therefore varied from cohort to cohort, are provided in Tables S1 and 
S2 in the Supplementary Appendix.
Sequencing and Genotyping
Sequence data for NPC1L1 were extracted from exome sequences generated at the Broad 
Institute, the Human Genome Sequencing Center at Baylor College of Medicine, or the 
University of Washington with the use of protocols that are described in the Supplementary 
Appendix. Briefly, sequence reads were aligned to the human reference genome (build 
HG19), and the basic alignment files for sequenced samples were combined for the purpose 
of identifying variant positions. Single-nucleotide variants (SNVs) and indels were 
identified, and quality control procedures were applied to remove outlier samples and outlier 
variants, as described in the Supplementary Appendix.
For the purposes of this study, we defined inactivating mutations as any one of the 
following: SNVs leading to a stop codon substitution (nonsense mutations), SNVs occurring 
within two base pairs of an exon–intron boundary (splice-site mutations), or DNA insertions 
or deletions leading to a change in the reading frame and the introduction of a premature 
stop codon (frameshift mutations). The positions of nonsense, splice-site, and frameshift 
mutations were based on the complementary DNA reference sequence for NPC1L1 
(NM_013389.2) with the ATG initiation codon, encoding methionine, numbered as residue 
1 or p.Met1.
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To obtain additional data for a particular nonsense mutation (p.Arg406X) observed from 
sequencing NPC1L1, we genotyped the variant site in additional samples using the 
HumanExome Bead-Chip Kit (Illumina), according to the manufacturer’s recommended 
protocol. (See the Methods section in the Supplementary Appendix for details.)
Technical Validation of Sequencing and Genotyping
To assess the accuracy of next-generation sequencing methods, we performed Sanger 
sequencing on samples obtained from all participants who carried inactivating mutations in 
the ATVB study. To assess the accuracy of the genotyping of NPC1L1 p.Arg406X with the 
HumanExome BeadChip kit, we compared these genotypes with those derived from next-
generation sequencing for a subset of samples.
Statistical Analysis
We first tested the association between NPC1L1 protein-inactivating mutations and plasma 
lipid levels. For participants who were receiving lipid-lowering therapy, we accounted for an 
average reduction in total cholesterol and LDL cholesterol levels of 20% and 30%, 
respectively,26 by adjusting the measured values accordingly. We did not adjust levels of 
high-density lipoprotein (HDL) cholesterol or triglycerides in these participants. Status with 
respect to the use of lipid-lowering medication was available for participants in ARIC, JHS, 
Munich-MI, PROCARDIS, REGICOR, and WGHS. When possible, we combined primary 
data for studies that included only one participant with an inactivating mutation with data for 
other studies involving participants of the same ancestry in order to create a larger data set. 
We performed regression analysis with a linear model that was adjusted for age and sex, 
along with an indicator variable for the study if applicable, to test for an association between 
the presence of inactivating mutations in NPC1L1 and levels of total cholesterol, LDL 
cholesterol, HDL cholesterol, and log-transformed triglyceride levels in each sample set. We 
combined results first within ancestry groups and then across ancestry groups, using fixed-
effects meta-analyses.
We next tested for an association between protein-inactivating mutations in NPC1L1 and the 
risk of coronary heart disease. In each study, we estimated the odds ratio for disease among 
carriers of any NPC1L1 inactivating mutation, as compared with noncarriers. We then 
calculated the summary odds ratios and 95% confidence intervals for coronary heart disease 
among carriers, using a Mantel–Haenszel fixed-effects meta-analysis without continuity 
correction, a method that is robust with low (and even zero) counts and resultant odds ratios. 
A P value of less than 0.05 was considered to indicate statistical significance. The R 
software program (R Project for Statistical Computing) was used for all analyses.
Results
Rare Inactivating Mutations in NPC1L1
After sequencing NPC1L1 in 7364 patients with coronary heart disease and in 14,728 
controls without such disease, we identified 15 mutations that were expected to inactivate 
NPC1L1 (Table 1). These mutations included 10 nonsense single-nucleotide substitutions, 3 
single-nucleotide substitutions that were predicted to disrupt splicing, and 2 frame-shift 
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indels (Fig. 1). In aggregate, these 15 mutations were seen in a total of 34 participants with 
heterozygous mutations; no homozygotes or compound heterozygotes were identified. 
NPC1L1 inactivating mutations were rare, with such variants found in approximately 1 in 
650 participants.
The most frequently observed individual mutation was p.Arg406X, which had a minor allele 
frequency of 0.02% among participants of European ancestry (seven alleles observed in 
29,198 chromosomes) and was not observed in participants of African or South Asian 
ancestry. We genotyped this single variant in an additional 22,590 participants with 
coronary heart disease and in 68,412 controls. Among these 91,002 participants, we 
identified 48 additional heterozygous carriers (Table 1). The baseline characteristics of 
participants carrying NPC1L1 inactivating mutations and those without such mutations were 
similar across all 16 studies (Table S3 in the Supplementary Appendix).
As a quality-control measure to assess the accuracy of next-generation sequencing, we 
performed Sanger sequencing and independently confirmed the presence of inactivating 
mutations in all carriers who were identified in the ATVB study. (See the Supplementary 
Appendix for details.) In a similar effort to assess the quality of genotyping, we compared 
genotype calls for p.Arg406X across 4092 samples that had undergone both genotyping and 
sequencing. On the basis of these data, we observed 100% specificity and sensitivity in 
identifying p.Arg406X carriers with the use of genotyping.
NPC1L1 Mutations and Plasma Lipid Levels
Plasma lipid measurements were available for 13,626 participants in the ARIC study, 2082 
in the JHS, and 22,515 in the WGHS. In addition, plasma lipid levels were available for 
5405 controls without coronary heart disease from the ATVB, ESP-EOMI, Munich-MI, 
OHS, PROCARDIS, and REGICOR studies. LDL cholesterol levels were available for 
42,813 of these 43,628 study participants. To minimize the effect of ascertainment bias, we 
excluded patients with coronary heart disease from case–control studies in the lipids 
analysis. As compared with noncarriers, carriers of inactivating NPC1L1 mutations had 
significantly lower levels of total cholesterol (mean adjusted difference, −13 mg per deciliter 
[0.34 mmol per liter]; P = 0.03) (Table 2) and LDL cholesterol (mean adjusted difference, 
−12 mg per deciliter [0.31 mmol per liter]; P = 0.04) (Table 2 and Fig. 2). Triglyceride 
levels were also reduced among carriers, although the difference was not significant (mean 
change, −12%; P = 0.11). We did not observe any significant difference in HDL cholesterol 
levels between carriers and non-carriers, with an increase of 2 mg per deciliter (0.05 mmol 
per liter) among carriers (P = 0.29). Participants of European and African ancestry had a 
similar magnitude of LDL reduction (−13 mg per deciliter and −10 mg per deciliter [0.26 
mmol per liter], respectively) (Fig. 2).
Association between NPC1L1 Mutations and coronary Risk
Carriers of the 15 inactivating mutations that we identified in NPC1L1 were 
underrepresented among patients with coronary heart disease, as compared with controls 
(Table 3). In total, only 11 participants among 29,954 patients with coronary heart disease 
had an inactivating mutation (carrier frequency, 0.04%) in contrast to 71 of 83,140 controls 
Page 5
N Engl J Med. Author manuscript; available in PMC 2015 May 27.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(carrier frequency, 0.09%). This represented a 53% reduction in the risk of coronary heart 
disease among carriers of inactivating NPC1L1 mutations (odds ratio for disease among 
carriers, 0.47; 95% confidence interval [CI], 0.25 to 0.87; P = 0.008) (Table 3, and Table S4 
in the Supplementary Appendix).
We observed a reduced risk of coronary heart disease among both participants of African 
descent and those of European descent. In the African ancestry subgroup, only 2 of 887 
patients with coronary heart disease carried an NPC1L1 inactivating mutation (carrier 
frequency, 0.23%), as compared with 13 of 4655 controls (carrier frequency, 0.28%), 
representing a 17% reduction in the risk of coronary heart disease among carriers (cohort-
based meta-analysis odds ratio, 0.83). In participants of European ancestry, 9 of 28,223 
patients with coronary heart disease carried the mutation (carrier frequency, 0.03%), as 
compared with 57 of 77,378 controls (carrier frequency, 0.07%), representing a 57% 
reduction in the risk of coronary heart disease among carriers (cohort-based meta-analysis 
odds ratio, 0.43).
Discussion
We sequenced the protein-coding regions of NPC1L1 in 22,092 participants and identified 
15 rare mutations that were expected to disrupt the protein. We also genotyped the most 
frequently observed of these inactivating mutations (p.Arg406X) in an additional 91,002 
participants. Carriers of any NPC1L1 inactivating mutation had a mean LDL cholesterol 
level that was 12 mg per deciliter lower than the level in noncarriers, along with a 53% 
lower risk of coronary heart disease. These results show that lifelong inactivation of one 
copy of NPC1L1 is protective against coronary heart disease. The observation that genetic 
inhibition of NPC1L1 reduces the risk of coronary heart disease increases the prior 
probability that pharmacologic inhibition of NPC1L1 will also reduce the risk of disease. In 
2002, ezetimibe was initially approved as a therapeutic agent in the United States on the 
basis of the capacity of the drug to lower LDL cholesterol levels. Although it has been 
assumed that any pharmacologic means of lowering LDL cholesterol levels will reduce the 
risk of coronary heart disease, the findings from the Ezetimibe and Simvastatin in 
Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial have led 
some observers to question this assumption.28 In ENHANCE, the addition of ezetimibe to 
background statin therapy in patients with familial hypercholesterolemia did not reduce the 
progression of carotid intima–media thickness, a surrogate measure for atherosclerosis.6 In 
the ongoing phase 3, randomized Improved Reduction of Outcomes: Vytorin Efficacy 
International Trial (IMPROVE-IT; ClinicalTrials .gov number, NCT00202878), 
investigators are evaluating whether the addition of ezetimibe to background simvastatin 
therapy will reduce the risk of recurrent cardiovascular events in patients with a recent acute 
coronary syndrome.29
Our findings do not predict with certainty that ezetimibe will be found to reduce 
cardiovascular risk in the IMPROVE-IT trial or other clinical studies, for several reasons. 
First, lifelong genetic inhibition, as tested in our study, has important differences from 
pharmacologic inhibition that is initiated in adulthood and lasts for several years. Second, 
our genetic study focuses on a first cardiovascular event, whereas IMPROVE-IT is 
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evaluating recurrent events. Finally, the net clinical benefit of a pharmacologic therapy is a 
complex interplay among multiple factors, including many that are specific to the drug (e.g., 
toxic effects) and that would not be tested in a genetic model such as the one used in our 
study.
The reduction in the risk of coronary heart disease (53%) that we observed among carriers 
exceeds the reduction that would be expected for a decrease of 12 mg per deciliter in LDL 
cholesterol on the basis of results from statin trials.26 Several factors may explain this 
difference. Modest reductions in plasma lipid levels over a lifetime, as achieved in carriers 
of an inactivating mutation, appear to lead to a larger modification of the risk of coronary 
heart disease than pharmacologic treatment that is initiated later in life. Such an effect has 
been observed in persons with genetic loss of function in several lipid genes.30 In addition to 
affecting LDL cholesterol levels, genetic loss of NPC1L1 function is associated with 
reduced plant sterol absorption.31,32 Levels of plant sterols are markedly elevated in patients 
with autosomal recessive sitosterolemia, a disease that is associated with accelerated 
atherosclerotic vascular disease even among patients without significantly elevated plasma 
LDL cholesterol levels.33 These observations raise the possibility that genetic inhibition of 
NPC1L1 may also lower the risk of coronary heart disease by reducing the absorption of 
noncholesterol sterols. Also, the effect of NPC1L1 inhibition on cardiovascular risk in our 
study may be overestimated owing to the “winner’s curse”34 phenomenon, in which the 
effects of newly discovered associations are inflated as compared with the true effect sizes. 
Our results suggest a broad range of plausible risk estimates associated with these mutations.
Several limitations of the study deserve mention. The combined statistical evidence 
supporting a protective association with coronary heart disease (P = 0.008) is significant for 
a test of a single hypothesis but falls short of the exomewide significance threshold that 
would be used to account for multiple hypothesis testing across all genes (P = 1.7×10−6 on 
the basis of a Bonferroni correction for 21,000 protein-coding and 9000 long noncoding 
RNA genes).35 This stringent threshold is used to limit false positive results of genetic 
association studies35 involving many hypotheses, in which the prior probability of a true 
association is low. Here, however, we have evaluated a gene that is known to alter LDL 
cholesterol levels, a proven causal factor for coronary heart disease. Therefore, the prior 
probability that this gene alters the risk of coronary heart disease is considerably higher than 
that for a random gene drawn from the genome.
In addition, we focused only on the classes of genetic variation — nonsense, splice-site, and 
frameshift — that are clearly expected to lead to a loss in NPC1L1 function and did not 
include missense variants. Although some missense mutations in NPC1L1 clearly inhibit 
function, many others have no effect on the protein.31,32,36,37 On average, the inclusion of 
neutral missense variants has been shown to dilute association signals and decrease 
statistical power.38 As a result of our focus on rare inactivating mutations, the associations 
that we discovered are based on a relatively modest number of observations. Finally, we 
were unable to evaluate whether NPC1L1 inactivating mutations lead to other phenotypic 
consequences.
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In conclusion, on the basis of sequencing and genotyping in 113,094 study participants, we 
found that inactivating mutations in NPC1L1 were associated with both reduced LDL 
cholesterol levels and a reduced risk of coronary heart disease. Whether pharmacologic 
therapies that are focused on inhibiting NPC1L1 function reduce the risk of coronary heart 
disease remains to be determined.
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Page 9
N Engl J Med. Author manuscript; available in PMC 2015 May 27.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical 
Research Institute at Harbor–UCLA Medical Center, Torrance (J.I.R.) — both in California; 
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Center for Public Health Genomics, University of Virginia, Charlottesville (S.S.R.); Center 
for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor 
(G.A.); the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (E.A., Z.Y., 
I.J.K.); the Departments of Medicine (P.E.W., C.M.S., J.C.D., D.M.R.), Biomedical 
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Figure 1. Inactivating Mutations in NPC1L1 Identified in the Study
Black circles indicate individual mutations along with the effect expected to lead to NPC1L1 
inactivation. Mutations p.L71RfsX50 and p.A296VfsX57 (red shading) are indels that shift 
the open reading frame and induce a premature termination codon after an additional 50 and 
57 amino acids, respectively. Mutations c.1681+1G→A, c.2637+2T→G, and p.A1201V (c.
3602C→T) (blue shading) alter the splicing process at sites of modification of the nascent 
pre-messenger RNA transcript (splice-site mutations). All other mutations (yellow shading) 
are single-nucleotide variants that introduce a termination codon. The locations of the three 
main extracellular domains, 13 transmembrane domains, and intracellular domains are based 
on data from Betters and Yu.27 NH2 denotes the N-terminal at which protein translation is 
initiated, and COOH the C-terminal at which translation terminates.
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Figure 2. Association between the Presence of Inactivating Mutations in NPC1L1 and LDL 
Cholesterol Levels, According to Genetic Ancestry
In each group of participants, we tested the association between the presence of inactivating 
mutations in NPC1L1 and plasma levels of low-density lipoprotein (LDL) cholesterol, after 
adjustment for age, sex, and study. The squares indicate the estimated adjusted difference in 
the LDL cholesterol level for carriers, as compared with noncarriers, in each ancestry group. 
The sizes of the squares are inversely proportional to the variance of the estimates. The 
diamonds indicate the combined results, based on a fixed-effects meta-analysis performed 
first within and then across ancestry groups. Participants from population-based studies — 
the Atherosclerosis Risk in Communities (ARIC) study, the Jackson Heart Study (JHS), and 
the Women’s Genome Health Study (WGHS) — and controls without coronary heart 
disease (CHD) from case–control studies were included in this analysis. To convert the 
values for cholesterol to millimoles per liter, multiply by 0.02586.
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Table 1
Inactivating Mutations in NPC1L1 in Participants from 16 Studies. *
Cohort and Mutation
Type of
Mutation
Study (No. of Participants/
No. of Carriers) Ancestry
Sequencing and genotyping
cohorts
All studies (113,094/82)
Sequencing cohort
    All participants† All studies in sequencing cohort(22,092/34)
    p.L71RfsX50 Frameshift ARIC (2836/1), JHS (2251/1) African
    p.Q167X Nonsense OHS (1953/1) European
    p.A296VfsX57 Frameshift ATVB (3539/3) European
    p.R406X Nonsense ATVB (3539/4), PROCARDIS (1902/1),
ARIC (5718/2)
European
    p.Y483X Nonsense PROMIS (1951/1) South Asian
    c.1681+1G→A Splice-site ARIC (2836/2), JHS (2251/1) African
    p.W592X Nonsense ARIC (5718/1) European
    p.R601X Nonsense ARIC (2836/1) African
    p.Q604X Nonsense ESP-EOMI (455/1), ARIC (2836/2) African
    p.R738X Nonsense REGICOR (783/2) European
    p.E803X Nonsense ARIC (5718/1) European
    c.2637+2T→G Splice-site ARIC (5718/1), Munich-MI (704/1) European
    p.C967X Nonsense ARIC (2836/1) African
    p.A1201V Splice-site JHS (2251/2) African
    p.R1325X Nonsense ARIC (2836 of African ancestry/1), JHS
(2251 of African ancestry/2), ARIC
(5718 of European ancestry/1)
African and
European
Genotyping cohort
    All participants‡ All studies in genotyping cohort(91,002/48)
    p.R406X Nonsense ARIC (5237/4), BioVU (21,143/12),
German North (7350/1), German
South (8176/3), GoDARTS
(3765/4), Mayo (2669/2),
PROCARDIS (2227/1), WGHS
(22,617/11), WHI (17,818/10)
European
*ARIC denotes Atherosclerosis Risk in Communities, ATVB Atherosclerosis Thrombosis and Vascular Biology, BioVU Vanderbilt University 
Medical Center Biorepository, ESP-EOMI Exome Sequencing Project Early-Onset Myocardial Infarction, German North German North Coronary 
Artery Disease Study, German South German South Coronary Artery Disease Study, GoDARTS Genetics of Diabetes Audit and Research Tayside, 
JHS Jackson Heart Study, Mayo Mayo Vascular Diseases Biorepository, Munich-MI Munich Myocardial Infarction, OHS Ottawa Heart Study, 
PROCARDIS Precocious Coronary Artery Disease, PROMIS Pakistan Risk of Myocardial Infarction Study, REGICOR Registre Gironi del COR, 
WGHS Women’s Genome Health Study, and WHI Women’s Health Initiative.
†
The number of participants in the sequencing cohort includes 7364 patients with coronary heart disease and 14,728 controls without such disease.
‡
The number of participants in the genotyping cohort includes 22,590 patients with coronary heart disease and 68,412 controls without such 
disease.
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Table 2
Association between the Presence of Inactivating Mutations in NPC1L1 and Plasma Lipid Levels.*
Variable
Mean Difference
between Carriers
and Noncarriers* P Value
Cholesterol (mg/dl)
    Total −13 0.03
    Low-density lipoprotein −12 0.04
    High-density lipoprotein 2 0.29
Triglycerides (% change) −12 0.11†
*
The mean difference is the summary effect estimate for carriers of inactivating mutations in NPC1L1, as compared with noncarriers, after 
adjustment for age, sex, and study. Participants from population-based studies (ARIC, JHS, and WGHS) and controls without coronary heart 
disease from case–control studies were included in this analysis. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586.
†
This P value was calculated with the use of natural log transformation of the values.
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